Osteoclast Differentiation in Bone Metabolism

Osteoclast differentiation is a vital process in skeletal health, driving bone resorption and contributing to the dynamic balance between bone formation and degradation. Osteoclasts originate from mononuclear macrophage precursors under the influence of key factors such as macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor-κB ligand (RANKL). Binding of RANKL to its receptor RANK on precursor cells activates intracellular cascades—including NF-κB, MAPK and calcium-dependent signalling—that culminate in induction of the transcription factor NFATc1. This master regulator orchestrates expression of osteoclast-specific genes such as tartrate-resistant acid phosphatase (TRAP), cathepsin K and the vacuolar ATPase subunit V0 d2, essential for formation of the ruffled border and bone-resorbing activity. Beyond its physiological role in remodelling, excessive osteoclastogenesis contributes to pathological bone loss in osteoporosis, arthritis and tumour-induced osteolysis. Recent advances have illuminated noncoding RNA regulators, epigenetic modifications and the crosstalk between immune and skeletal systems, underscoring the global significance of targeting osteoclast differentiation for therapeutic intervention across a spectrum of bone metabolic disorders.

Research from Nature Portfolio

Emerging work has revealed a protective role for the long noncoding RNA MALAT1 in bone homeostasis. Studies demonstrate that MALAT1 expression declines during osteoclastogenesis in both human and murine systems, and genetic ablation of Malat1 in mice leads to accelerated bone loss and increased susceptibility to metastatic bone lesions. Mechanistically, MALAT1 binds to the transcriptional cofactor TEAD3, inhibiting its interaction with NFATc1 and thereby attenuating the transcriptional programme essential for osteoclast differentiation. Restoration of Malat1 expression rescues bone density and restrains osteolytic lesions, highlighting MALAT1 as a novel epigenetic checkpoint of osteoclast activity with potential for targeted therapy.

An earlier foundational study investigated lycorine—an alkaloid derived from plant sources—and its capacity to suppress RANKL-induced osteoclastogenesis via inhibition of MAP kinase kinase activity. Lycorine treatment in vitro reduced osteoclast formation, disrupted pseudopodia development and lowered expression of osteoclast markers including NFATc1, c-Fos and cathepsin K. In vivo, lycorine administration protected against ovariectomy-induced bone loss and particle-induced osteolysis, establishing the therapeutic potential of natural compounds in modulating bone metabolism.

Osteoclast Differentiation in Bone Metabolism publication trend

The graph below shows the total number of articles in osteoclast differentiation in bone metabolism across all publications each year (not limited to Nature Index journals).

Technical terms

Osteoclastogenesis: Differentiation of monocyte/macrophage precursors into bone-resorbing osteoclasts.

RANKL: Ligand for RANK receptor that initiates signalling cascades essential for osteoclast differentiation.

NFATc1: Nuclear factor of activated T cells cytoplasmic 1, the master transcription factor driving osteoclast-specific gene expression.

MAPK pathways: Mitogen-activated protein kinase cascades that transduce extracellular signals to regulate gene transcription.

Long noncoding RNA (lncRNA): RNA transcripts longer than 200 nucleotides that regulate gene expression without encoding protein.

Bone resorption: Process by which osteoclasts degrade mineralised matrix, releasing calcium and other minerals.

References

1. Long noncoding RNA Malat1 protects against osteoporosis and bone metastasis. Nature Communications (2024).
2. Lycorine suppresses RANKL-induced osteoclastogenesis in vitro and prevents ovariectomy-induced osteoporosis and titanium particle-induced osteolysis in vivo. Scientific Reports (2015).
3. Periplogenin attenuates LPS-mediated inflammatory osteolysis through the suppression of osteoclastogenesis via reducing the NF-κB and MAPK signaling pathways. Cell Death Discovery (2024).
4. Madecassoside inhibits estrogen deficiency‐induced osteoporosis by suppressing RANKL‐induced osteoclastogenesis. Journal of Cellular and Molecular Medicine (2018).